Trump administration reclassifies medical marijuana to Schedule III

Federal rescheduling could reshape Alaska's medical cannabis framework as state weighs tax and licensing policy.

FILE — statehouse · B.D. Gilfry / CC BY-SA 2.0

The Trump administration's move to reschedule medical marijuana from Schedule I to Schedule III marks a significant federal policy shift with direct implications for Alaska's medical cannabis program. The reclassification, reported by Alaska Story on April 23, creates a new regulatory environment in which medical cannabis gains federal recognition of medicinal utility—a threshold change that may ease research, banking, and compliance burdens for qualifying providers and patients.

The timing intersects with Alaska's own legislative activity. In recent weeks, lawmakers have advanced a record sealing bill and a hemp regulation measure toward the governor, while considering a statewide marijuana sales tax. Schedule III status does not preempt state law but may clarify the relationship between state licensing and federal enforcement, potentially removing obstacles to tax collection and banking relationships that have complicated Alaska's market.

Key to watch: how Alaska's Department of Commerce and state lawmakers interpret Schedule III status when finalizing tax policy and hemp rules. The reclassification may also influence the state's stance on intoxicating hemp products, which have persisted in the market despite prior court rulings, and could affect future ballot measures on related substances.